These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16372881)

  • 1. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA; Wolf JJ; Kaplanski CV; Ledwith BJ
    Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of current preclinical testing strategies for bacterial vaccines.
    Falk LA; Chandler DK; Richman P
    Dev Biol Stand; 1998; 95():25-9. PubMed ID: 9855411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical safety assessment of vaccines and adjuvants.
    Wolf JJ; Kaplanski CV; Lebron JA
    Methods Mol Biol; 2010; 626():29-40. PubMed ID: 20099119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical excipient development: the need for preclinical guidance.
    Baldrick P
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of drug in control samples during toxicokinetic investigations--a Novartis perspective.
    Nicholls I; Kolopp M; Pommier F; Scheiwiller M
    Regul Toxicol Pharmacol; 2005 Jul; 42(2):172-8. PubMed ID: 15885865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability evaluation of vaccines: WHO approach.
    Knezevic I
    Biologicals; 2009 Nov; 37(6):357-9; discussion 421-3. PubMed ID: 19729320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study designs for the nonclinical safety testing of new vaccine products.
    Forster R
    J Pharmacol Toxicol Methods; 2012 Jul; 66(1):1-7. PubMed ID: 22561062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
    Hondeghem LM
    Eur J Pharmacol; 2008 Apr; 584(1):1-9. PubMed ID: 18304526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in the preclinical development of vaccines: evaluation of efficacy and systemic toxicity in the mouse using array technology.
    Regnström KJ
    Methods Mol Biol; 2008; 448():447-67. PubMed ID: 18370242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation and review of DNA vaccine products.
    Smith HA
    Dev Biol (Basel); 2000; 104():57-62. PubMed ID: 11713825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Goals of stability evaluation throughout the vaccine life cycle.
    Krause PR
    Biologicals; 2009 Nov; 37(6):369-78; discussion 421-3. PubMed ID: 19775911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of extraneous agents in vaccine starting materials.
    Rouby JC
    Biologicals; 2010 May; 38(3):354-7. PubMed ID: 20347331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.